Genomics Technical Seminar hosted by Dr Sam Olechnowicz
 

The Olink Proteomics Explore and Explore-HT system is now available at WEHI Genomics! 

Olink Explore offers multiplexed affinity protein quantification at high sensitivity and high-throughput for biomarker discovery and precision medicine from just a few microlitres of sample.
WEHI Olink Proteomics platform

To celebrate, we are hosting a launch event to discover the possibilities of this new platform. In-person attendance is highly encouraged for the seminar at WEHI, and stay afterwards for an informal mixer with refreshments to discuss projects. A streaming link will also be available for those who can’t attend, or get in touch with us at olink@wehi.edu.au to schedule a kick-off meeting. 

Davis Auditorium

Join via TEAMS

Including Q&A session

Followed by refreshments from 3pm

Prof Rory Bowden (Advanced Genomics Facility, WEHI & Melbourne University) 

-           Introduction to Olink Proteomics at the WEHI Advanced Genomics Facility

Dr Cindy Lawley (Senior Director, Population Health, Olink Proteomics)

-           Olink discovery to clinical implementation in cancer, obesity and neurological disease

-           Proteomics data unlocking therapeutic targets and corroborating pharma programs through large population health datasets

Cindy is passionate about innovation to make multiomic technologies easier and cheaper to measure.  Such advances are essential to lower barriers to implement scalable, reproducible discoveries that can be translated to the clinic to drive individualized medicine and health equity.  In over 14 years at Illumina and together with customers, she helped develop solutions to better understand genetic risk in diverse populations and holds several Excellence in Technology Transfer awards for her work leading Illumina’s Consortia Program.  She joined Olink in 2020 soon after the launch of the Explore Platform that leverages NGS as a high throughput proteomic readout.  At Olink, she drives population health initiatives, working closely with the UK Biobank, FinnGen, SCALLOP and other large cohort studies.

All welcome!